ResMed Inc.

ResMed Inc.

RMDNYSE / NASDAQHealthcareLarge cap

$235.63-$1.25 (-0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$28.2B
P/E
20.1x
EV / EBITDA
14.5x
Revenue
$5.1B
Net margin
27.2%
ROCE
23.6%

-3.4% over the last year

ResMed Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-4.0%
3M
+3.1%
6M
+12.3%
1Y
-3.4%
5Y
-9.5%

52-week range

Day change -$1.25 (-0.5%) from $237 to $236 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RMD, bought on each weekday since 2021.

News & filings

What ResMed filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 36.9 times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.

Read moreShow less

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
146.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$28.2B
P/E
20.1x
P/B
4.7x
EV / EBITDA
14.5x
EV / Sales
5.4x
P/S
5.5x
52-week high
$275.96
52-week low
$182.82

Profitability

Operating margin
32.8%
Net margin
27.2%
EBITDA margin
37.4%
ROE
23.5%
ROCE
23.6%
ROA
17.1%
Asset turnover
0.63

Growth

Revenue
$5.1B
Revenue growth, 1Y
9.8%
Revenue CAGR, 3Y
12.9%
Net profit growth, 1Y
37.2%
Free cash flow
$1.7B

Solvency

Current ratio
3.44
Debt / Equity
0.14
Debt / Assets
0.10
CFO / Net profit
1.25
Cash / Market cap
4.3%

Where the revenue went

Of every $100 of FY2025 revenue, $27 was left as net income.

ResMed Inc. income statement flow, FY2025
ResMed Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.1B
RevenueGross profit$3.1B
Gross profitResearch and development$331.3M
Gross profitSelling, general and administrative$991.0M
Gross profitOther operating expenses$45.3M
Gross profitOperating income$1.7B
Operating incomePretax income$1.7B
Operating incomeInterest and other expense$9.8M
Pretax incomeTax and other$276.8M
Pretax incomeNet income$1.4B

Revenue and net profit

Revenue grew 9.8% in FY2025; net profit is the dashed line.

ResMed Inc. revenue and net profit by fiscal year
ResMed Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.6B$779.4M
FY2023$4.2B$897.6M
FY2024$4.7B$1.0B
FY2025$5.1B$1.4B

Cash flows

FY2025: $1.8B from operations, $1.7B free after investment (dashed).

ResMed Inc. operating and free cash flow by fiscal year
ResMed Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$351.1M$195.1M
FY2023$693.3M$559.3M
FY2024$1.4B$1.3B
FY2025$1.8B$1.7B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$5.1B+9.8%1Y
EBITDA
$1.9B+20.2%1Y
Net profit
$1.4B+37.2%1Y
Cash from operations
$1.8B+25.0%1Y
Free cash flow
$1.7B+28.3%1Y
Revenue CAGR, 3Y
12.9%
Net profit CAGR, 3Y
21.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$5.1B$1.9B$1.4B$1.7B23.5%+9.8%+37.2%

Monthly returns

Month-by-month returns of RMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$8.2B
Liabilities$2.2B
Equity$6.0B
Paid-in capital$2.0B
Retained earnings$6.1B
Treasury stock$2.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RMD highlighted.

P/E against peers

RMD trades at 20.1x earnings against a peer median of 18.2x (a 11% premium).

Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ResMed Inc.RMDthis companyP/E ↑ premium$28.2B20.1x4.7x23.5%14.5x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
GE HealthCare Technologies Inc.GEHC$29.0B13.9x2.8x20.1%9.2x
Biogen Inc.BIIB$29.0B22.4x1.6x7.1%12.5x
DexCom, Inc.DXCM$28.0B33.5x10.2x30.5%21.0x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
Peer median—18.2x4.8x13.6%12.5x

Year-to-date ROI

RMD since 1 January, against earlier years.

Historical volatility

RMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ResMed Inc. operating margin by fiscal year
ResMed Inc. operating margin by fiscal year
DateOperating margin
FY202228.0%
FY202327.3%
FY202429.5%
FY202532.8%
LineFY2025
Cost of revenueCost Of Revenue$2.1B
Gross profitGross Profit$3.1B
Operating expensesOperating Expense$1.4B
Research and developmentResearch And Development$331.3M
Selling, general and administrativeSelling General And Administration$991.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$45.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$45.3M
Amortization$45.3M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$45.3M
Total expensesTotal Expenses$3.5B
Pretax incomePretax Income$1.7B

Learn while you research

Academy chapters picked for ResMed Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →